SGLT2 Inhibitors Linked to Less Renal Deterioration Across All CKD Stages
Treatment with SGLT2 inhibitors empagliflozin and dapagliflozin may be associated with less decline in kidney function across different chronic kidney disease stages.
Treatment with SGLT2 inhibitors empagliflozin and dapagliflozin may be associated with less decline in kidney function across different chronic kidney disease stages.